Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

With AI demand in focus, CoreWeave’s IPO is expected to serve as a key test of whether ... in AI-related data center demand won’t be as strong as previously thought, meaning investors will either ...